Key result
Perioperative statins show potential for reducing morbidity, though optimal dosing and mechanisms remain unconfirmed.
Why the study?
Despite extensive clinical use and trial data, the full mechanisms and potential new indications of statins, including peri-operative morbidity and mortality prevention, remain incompletely understood.
Answers are grounded in this paper and cite their sources.
Incomplete statin mechanisms limit peri-operative risk reduction; leaves open optimal dosing, timing, and utility.
Despite over 20 years of clinical use and 15 years of clinical trial data, we still do not have a complete understanding of the mechanisms of action or full utility of statins as a class of drugs. The possibility of their use as a treatment for prevention of peri-operative morbidity and mortality is one of the newest indications being explored for this class of drugs. Issues regarding drug dosing and timing may rely on being able to elucidate and separate potential pleiotropic actions from lipid-lowering actions to identify the optimal benefit of these drugs in the peri-operative setting. Careful consideration of these two actions need to be considered in the design of adequately powered clinical trials to test the potential utility and safety of using statins in the peri-operative setting.
No takes yet. Share an insight, caveat, or question.
Michael A. Blazing (2010) conducted a review in Peri-operative morbidity and mortality. Statins was evaluated. Statins are being explored for the prevention of peri-operative morbidity and mortality, though further clinical trials are needed to determine optimal dosing and mechanisms of action.
Synapse has enriched 10 related papers. Consider them for comparative context: